Posted by Michael Wonder on 18 Mar 2021
Stimdia Medical receives FDA breakthrough device designation for the pdSTIM system designed to facilitate weaning patients from mechanical ventilation
18 March 2021 - Stimdia Medical today announced the company’s pdSTIM system has received breakthrough device designation from the U.S. FDA.
This system will provide clinicians a tool to address high risk patients, including those with COVID-19, by providing a minimally invasive neurostimulation solution to awaken and recondition the diaphragm, the primary muscle utilised in support of respiration.
